| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Profit or loss [abstract] | ||||||
| Grant income | ||||||
| Operating income | ||||||
| Research and development expenses | ||||||
| General and administrative expenses | ||||||
| Merger and listing expense | — | |||||
| Operating expenses | ||||||
| Operating loss | ||||||
| Finance income | ||||||
| Finance expense | ||||||
| Fair value adjustment on warrant liabilities | ||||||
| Foreign currency exchange gain (loss) | ||||||
| Finance result | ||||||
| Loss before tax for the period | ||||||
| Income tax benefit (expense) | ||||||
| Loss for the period | ||||||
| Loss per share [abstract] | ||||||
| Basic, loss attributable to equity holders | ||||||
| Diluted, loss attributable to equity holders |